SG11202011886TA - PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF - Google Patents

PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF

Info

Publication number: SG11202011886TA
Authority: SG; Singapore
Prior art keywords: composition; preparation methods; formulation containing; pharmaceutical combination; glucosidase inhibitor
Prior art date: 2018-05-31

Application number

SG11202011886TA

Inventor

Li Chen

Yongguo Li

Gaosen Wang

Huisheng Gao

Original Assignee

Hua Medicine Shanghai Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-31

Filing date

2019-05-28

Publication date

2020-12-30

2019-05-28 Application filed by Hua Medicine Shanghai Ltd filed Critical Hua Medicine Shanghai Ltd

2020-12-30 Publication of SG11202011886TA publication Critical patent/SG11202011886TA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

SG11202011886TA 2018-05-31 2019-05-28 PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF SG11202011886TA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201810556685		2018-05-31
PCT/CN2019/088865 WO2019228366A1 (en)	2018-05-31	2019-05-28	PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND α-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF

Publications (1)

Publication Number	Publication Date
SG11202011886TA true SG11202011886TA (en)	2020-12-30

Family

ID=68697184

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
SG11202011886TA SG11202011886TA (en)	2018-05-31	2019-05-28	PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF
SG11202011884QA SG11202011884QA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and sglt-2 inhibitor and preparation methods and uses thereof
SG11202011893UA SG11202011893UA (en)	2018-05-31	2019-05-28	Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof
SG11202011881PA SG11202011881PA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and dpp-iv inhibitor, and preparation method and use thereof
SG11202011888VA SG11202011888VA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition and compound preparation containing glucokinase activator and k-atp channel blocker, preparation method therefor and use thereof
SG11202011883RA SG11202011883RA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
SG11202011884QA SG11202011884QA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and sglt-2 inhibitor and preparation methods and uses thereof
SG11202011893UA SG11202011893UA (en)	2018-05-31	2019-05-28	Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof
SG11202011881PA SG11202011881PA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and dpp-iv inhibitor, and preparation method and use thereof
SG11202011888VA SG11202011888VA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition and compound preparation containing glucokinase activator and k-atp channel blocker, preparation method therefor and use thereof
SG11202011883RA SG11202011883RA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof

Country Status (14)

Country	Link
US (7)	US20210214343A1 (en)
EP (6)	EP3804715A4 (en)
JP (12)	JP2021535893A (en)
KR (6)	KR20210016436A (en)
CN (12)	CN110548026B (en)
AU (6)	AU2019278015A1 (en)
BR (6)	BR112020024203A2 (en)
CA (6)	CA3101822A1 (en)
IL (6)	IL279039A (en)
MX (6)	MX2020012969A (en)
RU (1)	RU2770775C1 (en)
SG (6)	SG11202011886TA (en)
TW (6)	TWI794503B (en)
WO (6)	WO2019228364A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11872221B2 (en)	2020-01-31	2024-01-16	Hua Medicine (Shanghai) Ltd.	Treating untreated or treatment-resistant diabetes with glucokinase activator
AU2020426356A1 (en) *	2020-01-31	2022-08-25	Hua Medicine (Shanghai) Ltd.	Treating treatment-resistant diabetes with glucokinase activator
US11813274B2 (en)	2020-04-22	2023-11-14	Hua Medicine (Shanghai) Ltd.	Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
CA3181882A1 (en) *	2020-04-22	2021-10-28	Hua Medicine (Shanghai) Ltd.	Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
WO2021243646A1 (en) *	2020-06-04	2021-12-09	Hua Medicine (Shanghai) Ltd.	Glucokinase activator for treating diabetes with hepatic impairment
WO2021243645A1 (en) *	2020-06-04	2021-12-09	Hua Medicine (Shanghai) Ltd.	Glucokinase activator for treating diabetes with renal impairment
US11857536B2 (en)	2020-06-04	2024-01-02	Hua Medicine (Shanghai) Ltd.	Glucokinase activator for treating diabetes with renal impairment
CN111759838B (en) *	2020-07-02	2022-01-25	深圳微芯生物科技股份有限公司	Pharmaceutical composition of pharmaceutically acceptable salt of sitagliptin and application thereof
CN112206216B (en) *	2020-10-15	2023-03-17	江西华士药业有限公司	Preparation method of sustained-release dapagliflozin
CN116234545A (en) *	2020-11-19	2023-06-06	北京睿创康泰医药研究院有限公司	Composition of fixed dose SGLT-2 inhibitor and angiotensin converting enzyme inhibitor and application
CN113527265B9 (en) *	2021-02-02	2022-07-19	湖南南新制药股份有限公司	Deuterated pyrrolidone derivative, pharmaceutical composition and application thereof
CN113750100B (en) *	2021-08-31	2022-12-30	海南中济医药科技有限公司	Pharmaceutical composition containing polyagliflozin Ai Ting and sitagliptin and preparation method thereof
AR127064A1 (en) *	2021-09-15	2023-12-13	Hua Medicine Shanghai Ltd	PRODRUGS OF PYRROLIDONE DERIVATIVES AS A GLUCOKINASE ACTIVATOR
WO2024005755A1 (en) *	2022-06-29	2024-01-04	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A tablet comprising empagliflozin

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9511220D0 (en) *	1995-06-02	1995-07-26	Glaxo Group Ltd	Solid dispersions
CA2560286A1 (en)	2004-03-23	2005-09-29	Banyu Pharmaceutical Co., Ltd.	Substituted quinazoline or pyridopyrimidine derivative
PE20080251A1 (en)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	USES OF DPP IV INHIBITORS
US7910747B2 (en) *	2006-07-06	2011-03-22	Bristol-Myers Squibb Company	Phosphonate and phosphinate pyrazolylamide glucokinase activators
US20080107725A1 (en) *	2006-10-13	2008-05-08	Albano Antonio A	Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
EA018495B1 (en) *	2006-11-09	2013-08-30	Бёрингер Ингельхайм Интернациональ Гмбх	Combination therapy with sglt-2 (sodium dependent glucose co-transporter) inhibitors and their pharmaceutical compositions
EP3078662A1 (en)	2007-09-21	2016-10-12	Array Biopharma, Inc.	Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
US7741327B2 (en) *	2008-04-16	2010-06-22	Hoffmann-La Roche Inc.	Pyrrolidinone glucokinase activators
BRPI0912802A2 (en)	2008-05-16	2015-10-13	Takeda San Diego Inc	glycokinase activators
TWI472525B (en)	2008-12-05	2015-02-11	Otsuka Pharma Co Ltd	Quinolone compound and pharmaceutical composition
JP2012517977A (en)	2009-02-13	2012-08-09	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	An anti-diabetic drug comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other anti-diabetic drugs
EA018894B1 (en) *	2009-03-11	2013-11-29	Пфайзер Инк.	N,n-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide used as glucokinase activator and pharmaceutical composition containing same
WO2010107610A1 (en)	2009-03-17	2010-09-23	Merck Sharp & Dohme Corp.	Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds
US8685934B2 (en) *	2009-05-27	2014-04-01	Bristol-Myers Squibb Company	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
EP2498757A1 (en) *	2009-11-13	2012-09-19	Bristol-Myers Squibb Company	Reduced mass metformin formulations
CA2780941C (en) *	2009-11-13	2018-06-12	Bristol-Myers Squibb Company	Immediate release tablet formulations
EA032085B1 (en) *	2010-05-26	2019-04-30	виТиви ТЕРАПЬЮТИКС ЭлЭлСи	Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
CN102558167A (en) *	2010-12-29	2012-07-11	中国医学科学院药物研究所	Thiazolidine derivant with GK and PPAR double excitation activity
JP6234443B2 (en) *	2012-05-17	2017-11-22	ブイティーブイ・セラピューティクス・エルエルシー	Glucokinase activator composition for the treatment of diabetes
SG11201503716RA (en)	2012-11-13	2015-06-29	Nissan Chemical Ind Ltd	2-pyridone compound
TW201446286A (en) *	2013-01-31	2014-12-16	Gilead Pharmasset Llc	Solid dispersion formulation of an antiviral compound
CN104208034B (en) *	2013-12-11	2017-11-07	重庆康刻尔制药有限公司	A kind of Glimepiride medicinal composition tablets, preparation method and applications
CN104840960A (en) *	2014-02-14	2015-08-19	广东东阳光药业有限公司	Antidiabetic pharmaceutical composition and preparation method thereof
AR099936A1 (en) *	2014-04-04	2016-08-31	Sanofi Sa	CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
WO2015176267A1 (en) *	2014-05-22	2015-11-26	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
CN106474480A (en) *	2016-11-15	2017-03-08	深圳奥萨医疗有限公司	Medical composition and its use containing glucokinase activator and B family vitamin
CN107854435B (en) *	2016-12-15	2019-01-22	华领医药技术（上海）有限公司	Oral preparation of glucokinase activators and preparation method thereof

2019
- 2019-05-28 CN CN201910453723.XA patent/CN110548026B/en active Active
- 2019-05-28 WO PCT/CN2019/088863 patent/WO2019228364A1/en active Application Filing
- 2019-05-28 JP JP2020566718A patent/JP2021535893A/en active Pending
- 2019-05-28 WO PCT/CN2019/088862 patent/WO2019228363A1/en active Application Filing
- 2019-05-28 US US17/058,883 patent/US20210214343A1/en active Pending
- 2019-05-28 EP EP19811377.1A patent/EP3804715A4/en active Pending
- 2019-05-28 EP EP19811691.5A patent/EP3804716A4/en active Pending
- 2019-05-28 KR KR1020207037950A patent/KR20210016436A/en not_active Application Discontinuation
- 2019-05-28 US US17/058,863 patent/US11666556B2/en active Active
- 2019-05-28 MX MX2020012969A patent/MX2020012969A/en unknown
- 2019-05-28 CA CA3101822A patent/CA3101822A1/en active Pending
- 2019-05-28 MX MX2020012970A patent/MX2020012970A/en unknown
- 2019-05-28 US US17/058,929 patent/US20210214312A1/en active Pending
- 2019-05-28 EP EP19812252.5A patent/EP3811939A4/en active Pending
- 2019-05-28 US US17/058,903 patent/US11963947B2/en active Active
- 2019-05-28 CN CN201910453076.2A patent/CN110548146B/en active Active
- 2019-05-28 CN CN201910453726.3A patent/CN110548149B/en active Active
- 2019-05-28 BR BR112020024203-9A patent/BR112020024203A2/en unknown
- 2019-05-28 JP JP2020566720A patent/JP2021525741A/en active Pending
- 2019-05-28 CA CA3101826A patent/CA3101826A1/en active Pending
- 2019-05-28 CN CN201910453724.4A patent/CN110548027B/en active Active
- 2019-05-28 JP JP2020566564A patent/JP7479696B2/en active Active
- 2019-05-28 WO PCT/CN2019/088861 patent/WO2019228362A1/en active Application Filing
- 2019-05-28 US US17/059,148 patent/US20210196683A1/en active Pending
- 2019-05-28 EP EP19810441.6A patent/EP3804713A4/en active Pending
- 2019-05-28 MX MX2020012966A patent/MX2020012966A/en unknown
- 2019-05-28 MX MX2020012972A patent/MX2020012972A/en unknown
- 2019-05-28 SG SG11202011886TA patent/SG11202011886TA/en unknown
- 2019-05-28 SG SG11202011884QA patent/SG11202011884QA/en unknown
- 2019-05-28 BR BR112020024107-5A patent/BR112020024107A2/en unknown
- 2019-05-28 BR BR112020024125-3A patent/BR112020024125A2/en unknown
- 2019-05-28 RU RU2020143045A patent/RU2770775C1/en active
- 2019-05-28 BR BR112020024269-1A patent/BR112020024269A2/en unknown
- 2019-05-28 KR KR1020207037560A patent/KR20210016416A/en not_active Application Discontinuation
- 2019-05-28 CA CA3101825A patent/CA3101825A1/en active Pending
- 2019-05-28 CN CN202111601625.XA patent/CN114010793A/en active Pending
- 2019-05-28 CA CA3101829A patent/CA3101829A1/en active Pending
- 2019-05-28 KR KR1020207038034A patent/KR20210014168A/en not_active Application Discontinuation
- 2019-05-28 SG SG11202011893UA patent/SG11202011893UA/en unknown
- 2019-05-28 MX MX2020012967A patent/MX2020012967A/en unknown
- 2019-05-28 WO PCT/CN2019/088866 patent/WO2019228367A1/en active Application Filing
- 2019-05-28 AU AU2019278015A patent/AU2019278015A1/en active Pending
- 2019-05-28 KR KR1020207037642A patent/KR20210016421A/en not_active Application Discontinuation
- 2019-05-28 SG SG11202011881PA patent/SG11202011881PA/en unknown
- 2019-05-28 CN CN202111599185.9A patent/CN114028574A/en active Pending
- 2019-05-28 CN CN202111601610.3A patent/CN114246950A/en active Pending
- 2019-05-28 AU AU2019278014A patent/AU2019278014A1/en active Pending
- 2019-05-28 JP JP2020566710A patent/JP2021525739A/en active Pending
- 2019-05-28 EP EP19810783.1A patent/EP3804714A4/en active Pending
- 2019-05-28 KR KR1020207037631A patent/KR20210016420A/en not_active Application Discontinuation
- 2019-05-28 JP JP2020566565A patent/JP2021525722A/en active Pending
- 2019-05-28 AU AU2019278013A patent/AU2019278013A1/en active Pending
- 2019-05-28 BR BR112020024271-3A patent/BR112020024271A2/en unknown
- 2019-05-28 US US17/058,936 patent/US20210212991A1/en active Pending
- 2019-05-28 AU AU2019278018A patent/AU2019278018A1/en active Pending
- 2019-05-28 AU AU2019278016A patent/AU2019278016A1/en active Pending
- 2019-05-28 WO PCT/CN2019/088864 patent/WO2019228365A1/en active Application Filing
- 2019-05-28 CN CN201910453725.9A patent/CN110548148B/en active Active
- 2019-05-28 CA CA3101832A patent/CA3101832A1/en active Pending
- 2019-05-28 KR KR1020207037957A patent/KR20210016437A/en not_active IP Right Cessation
- 2019-05-28 WO PCT/CN2019/088865 patent/WO2019228366A1/en active Application Filing
- 2019-05-28 CA CA3101831A patent/CA3101831A1/en active Pending
- 2019-05-28 JP JP2020566675A patent/JP7265276B2/en active Active
- 2019-05-28 EP EP19810210.5A patent/EP3804712A4/en active Pending
- 2019-05-28 SG SG11202011888VA patent/SG11202011888VA/en unknown
- 2019-05-28 BR BR112020024348-5A patent/BR112020024348A2/en unknown
- 2019-05-28 CN CN201910453079.6A patent/CN110548147B/en active Active
- 2019-05-28 SG SG11202011883RA patent/SG11202011883RA/en unknown
- 2019-05-28 CN CN202111599339.4A patent/CN114209694A/en active Pending
- 2019-05-28 CN CN202111599191.4A patent/CN114159570A/en active Pending
- 2019-05-28 AU AU2019278017A patent/AU2019278017A1/en active Pending
- 2019-05-28 CN CN202111601620.7A patent/CN114259491A/en active Pending
- 2019-05-28 MX MX2020012965A patent/MX2020012965A/en unknown
- 2019-05-31 TW TW108118901A patent/TWI794503B/en active
- 2019-05-31 TW TW108118939A patent/TWI706947B/en active
- 2019-05-31 TW TW108118940A patent/TWI778268B/en active
- 2019-05-31 TW TW108118937A patent/TWI765157B/en active
- 2019-05-31 TW TW108118936A patent/TWI764000B/en active
- 2019-05-31 TW TW108118896A patent/TWI761681B/en active
2020
- 2020-11-27 IL IL279039A patent/IL279039A/en unknown
- 2020-11-27 IL IL279037A patent/IL279037A/en unknown
- 2020-11-27 IL IL279034A patent/IL279034A/en unknown
- 2020-11-27 IL IL279035A patent/IL279035A/en unknown
- 2020-11-27 IL IL279036A patent/IL279036A/en unknown
- 2020-11-27 IL IL279040A patent/IL279040A/en unknown
2022
- 2022-11-07 JP JP2022178269A patent/JP2022190162A/en active Pending
- 2022-11-07 JP JP2022178345A patent/JP2022190168A/en active Pending
- 2022-11-07 JP JP2022178201A patent/JP2022190159A/en active Pending
- 2022-11-07 JP JP2022178239A patent/JP2022190161A/en active Pending
- 2022-11-07 JP JP2022178296A patent/JP2022190165A/en active Pending
- 2022-11-07 JP JP2022178385A patent/JP2022190170A/en active Pending
2023
- 2023-05-03 US US18/311,846 patent/US20230346748A1/en active Pending

Also Published As

Publication number	Publication date
CN114259491A (en)	2022-04-01
RU2770775C1 (en)	2022-04-21
MX2020012965A (en)	2021-02-16
JP2021525741A (en)	2021-09-27
TWI778268B (en)	2022-09-21
BR112020024125A2 (en)	2021-02-17
EP3804716A1 (en)	2021-04-14
WO2019228364A1 (en)	2019-12-05
CN110548149A (en)	2019-12-10
EP3811939A1 (en)	2021-04-28
MX2020012970A (en)	2021-02-16
JP7479696B2 (en)	2024-05-09
EP3804716A4 (en)	2022-05-25
CN110548026B (en)	2022-01-14
AU2019278016A1 (en)	2021-01-21
TW202003500A (en)	2020-01-16
US11666556B2 (en)	2023-06-06
CN110548148B (en)	2022-01-14
US20210196682A1 (en)	2021-07-01
CN110548146B (en)	2022-01-14
CN110548148A (en)	2019-12-10
TWI706947B (en)	2020-10-11
RU2770043C1 (en)	2022-04-14
JP2022190165A (en)	2022-12-22
MX2020012966A (en)	2021-02-16
CN110548147A (en)	2019-12-10
WO2019228367A1 (en)	2019-12-05
US20210220334A1 (en)	2021-07-22
JP2022190162A (en)	2022-12-22
EP3804712A4 (en)	2022-05-25
EP3804713A4 (en)	2022-03-02
KR20210014168A (en)	2021-02-08
US20210196683A1 (en)	2021-07-01
CN114209694A (en)	2022-03-22
MX2020012969A (en)	2021-02-16
IL279035A (en)	2021-01-31
JP2022190159A (en)	2022-12-22
KR20210016416A (en)	2021-02-15
TW202003501A (en)	2020-01-16
SG11202011883RA (en)	2020-12-30
KR20210016421A (en)	2021-02-15
TWI761681B (en)	2022-04-21
KR20210016437A (en)	2021-02-15
CA3101831A1 (en)	2019-12-05
CN110548027B (en)	2022-01-14
CN114010793A (en)	2022-02-08
BR112020024269A2 (en)	2021-02-23
KR20210016420A (en)	2021-02-15
US20210214343A1 (en)	2021-07-15
TWI765157B (en)	2022-05-21
CN114246950A (en)	2022-03-29
EP3804715A1 (en)	2021-04-14
SG11202011888VA (en)	2020-12-30
JP2021525721A (en)	2021-09-27
CN110548147B (en)	2022-01-14
AU2019278018A1 (en)	2021-01-21
JP7265276B2 (en)	2023-04-26
TW202003502A (en)	2020-01-16
US20210214312A1 (en)	2021-07-15
CN114028574A (en)	2022-02-11
US11963947B2 (en)	2024-04-23
CN110548149B (en)	2022-01-14
CN110548146A (en)	2019-12-10
AU2019278015A1 (en)	2021-01-07
IL279039A (en)	2021-01-31
SG11202011893UA (en)	2020-12-30
EP3804713A1 (en)	2021-04-14
TW202003499A (en)	2020-01-16
AU2019278013A1 (en)	2021-01-21
JP2022190168A (en)	2022-12-22
BR112020024271A2 (en)	2021-02-23
CN110548026A (en)	2019-12-10
CA3101832A1 (en)	2019-12-05
IL279040A (en)	2021-01-31
TW202003464A (en)	2020-01-16
CA3101829A1 (en)	2019-12-05
WO2019228365A1 (en)	2019-12-05
WO2019228366A1 (en)	2019-12-05
US20210212991A1 (en)	2021-07-15
WO2019228363A1 (en)	2019-12-05
KR20210016436A (en)	2021-02-15
IL279036A (en)	2021-01-31
SG11202011884QA (en)	2020-12-30
EP3804714A4 (en)	2022-05-25
CA3101825A1 (en)	2019-12-05
BR112020024107A2 (en)	2021-02-17
CN114159570A (en)	2022-03-11
BR112020024203A2 (en)	2021-02-17
JP2022190170A (en)	2022-12-22
US20230346748A1 (en)	2023-11-02
EP3804714A1 (en)	2021-04-14
AU2019278017A1 (en)	2021-01-21
BR112020024348A2 (en)	2021-02-23
AU2019278014A1 (en)	2021-01-21
EP3804712A1 (en)	2021-04-14
IL279037A (en)	2021-01-31
CA3101826A1 (en)	2019-12-05
CN110548027A (en)	2019-12-10
WO2019228362A1 (en)	2019-12-05
EP3811939A4 (en)	2022-05-25
MX2020012967A (en)	2021-02-16
TWI764000B (en)	2022-05-11
JP2021525722A (en)	2021-09-27
JP2021535893A (en)	2021-12-23
JP2022190161A (en)	2022-12-22
JP2021525733A (en)	2021-09-27
TWI794503B (en)	2023-03-01
EP3804715A4 (en)	2022-05-25
IL279034A (en)	2021-01-31
TW202003498A (en)	2020-01-16
JP2021525739A (en)	2021-09-27
MX2020012972A (en)	2021-02-16
SG11202011881PA (en)	2020-12-30
CA3101822A1 (en)	2019-12-05

Publication	Publication Date	Title
SG11202011886TA (en)	2020-12-30	PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF
EP3835296A4 (en)	2022-05-18	Ketoamide compound and preparation method, pharmaceutical composition, and use thereof
CA2956871C (en)	2021-05-18	Compounds active towards bromodomains
EP3891149A4 (en)	2022-09-07	Ret inhibitors, pharmaceutical compositions and uses thereof
EP3434676A4 (en)	2019-09-11	Substituted pyrrolopyrimidine cdk inhibitor, pharmaceutical composition containing same and use thereof
EP3706741A4 (en)	2022-03-30	Pharmaceutical composition and use thereof
EP3673897A4 (en)	2021-05-05	Injectable pharmaceutical composition containing meloxicam, and preparation method therefor
EP3891148A4 (en)	2022-09-07	Ret inhibitors, pharmaceutical compositions and uses thereof
EP3825308A4 (en)	2022-05-11	Compound, composition, and use thereof in preparation of drug
EP3858353A4 (en)	2022-07-06	Pharmaceutical composition for preventing and treating nitm and pharmaceutical use thereof
EP3677126A4 (en)	2021-06-23	Ages inhibitor composition, use thereof, preparation method therefor, and formulation thereof
EP3697411A4 (en)	2021-08-18	Novel pharmaceutical composition and use thereof
EP3770148A4 (en)	2022-01-05	Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
EP3760191A4 (en)	2021-05-05	Pharmaceutical composition and preparation method therefor and use thereof
MX2018014790A (en)	2019-04-25	Combination formulation of three antiviral compounds.
EP3456711A4 (en)	2019-10-16	Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof
EP3858812A4 (en)	2022-07-06	Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP3733670A4 (en)	2022-01-26	Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
EP3624779A4 (en)	2022-07-06	Modified release pharmaceutical compositions of huperzine and methods of using the same
EP3612185A4 (en)	2021-02-24	Pharmaceutical compositions comprising poh derivatives and methods of use
EP3404054A4 (en)	2019-11-13	Pharmaceutical composition comprising 5-dodecanolide, preparation thereof and use of same
IL284132A (en)	2021-08-31	Pharmaceutical compound, the method of its making and use as medicinal agent
EP3210614A4 (en)	2018-06-13	Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
SG11202010069SA (en)	2020-11-27	Dipeptide and pharmaceutical composition containing same
EP3804722A4 (en)	2022-04-13	Treatment agent and pharmaceutical composition for glioma